Arcturus Therapeutics (ARCT) News Today $12.00 +0.46 (+3.99%) Closing price 04:00 PM EasternExtended Trading$11.99 -0.01 (-0.08%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock Why Is Arcturus Therapeutics Up Today?Toggle Visibility of Why Is Arcturus Therapeutics Up Today?Arcturus Therapeutics Holdings Inc. (ARCT) — Shares are trading lower overall after interim Phase 2 cystic fibrosis (CF) data released last week were widely viewed as mixed/underwhelming and triggered a sharp selloff. The decline prompted multiple analyst rating changes and steep cuts to price targets; however, a few firms remain constructive at reduced targets. Below are the items most likely driving today's action. Positive Sentiment: BTIG cut its price target from $48 to $23 but kept a "buy" rating, signaling some analysts still see multi‑month upside despite the weak data. BTIG Research Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Positive Sentiment: Wells Fargo lowered its target from $42 to $20 but maintained an "overweight" rating, implying the stock still has meaningful upside from current levels in their view. Arcturus Therapeutics (NASDAQ:ARCT) Given New $20.00 Price Target at Wells Fargo & Company Neutral Sentiment: Coverage pieces are framing the situation as a pivotal reset for Arcturus: some view the CF readout as a setback that re-writes the story, while others are parsing subgroup and safety data for salvageable value. How Recent Shifts Are Rewriting the Story for Arcturus Therapeutics Holdings Negative Sentiment: Arcturus released interim Phase 2 data for its mRNA‑tied CF program that investors judged mixed/underwhelming, the primary catalyst for the ensuing selloff. Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program Negative Sentiment: Following the readout, shares plunged sharply in after‑hours/early trading on Oct. 22 — headlines report declines of ~50%+, signaling heavy liquidation and sentiment deterioration. Arcturus Shares Plunge After Midstage Trial Data Negative Sentiment: Multiple brokers downgraded or cut targets: Guggenheim moved ARCT to neutral, and Citigroup downgraded to neutral and cut its target to $12 — both actions increase near‑term selling pressure. Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Neutral Rating by Guggenheim Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Citigroup Bottom line for investors: the CF Phase 2 readout is the proximate cause of the selloff and analyst re‑ratings. Watch for company commentary, full data release and any guidance on next steps; those items will determine whether the remaining bullish analyst views (at reduced targets) can stabilize the stock. Posted 2h agoAI Generated. May Contain Errors. ARCT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period BTIG Research Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price4 hours ago | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Given New $20.00 Price Target at Wells Fargo & CompanyOctober 23 at 9:43 AM | marketbeat.comHow Recent Shifts Are Rewriting the Story for Arcturus Therapeutics HoldingsOctober 23 at 8:53 AM | finance.yahoo.comArcturus Therapeutics Announces Phase 2 Trial ResultsOctober 23 at 8:53 AM | theglobeandmail.comArcturus Crashes 50% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis DrugOctober 23 at 8:53 AM | msn.comArcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by CitigroupOctober 23 at 8:44 AM | marketbeat.comArcturus Shares Plunge After Midstage Trial DataOctober 22 at 8:08 PM | marketwatch.comWhere Arcturus Therapeutics Stands With AnalystsOctober 22 at 8:08 PM | benzinga.comArcturus falls after mid-stage study data for cystic fibrosis treatmentOctober 22 at 8:08 PM | msn.comArcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial dataOctober 22 at 8:08 PM | msn.comArcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) ProgramOctober 22 at 8:08 PM | finance.yahoo.comArcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug resultsOctober 22 at 8:08 PM | msn.comArcturus Crashes 60% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis DrugOctober 22 at 8:08 PM | msn.comArcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis DrugOctober 22 at 10:01 AM | investors.comARK Investment Management LLC Has $22.31 Million Stake in Arcturus Therapeutics Holdings Inc. $ARCTOctober 22 at 9:12 AM | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Lowered to Neutral Rating by GuggenheimOctober 22 at 9:11 AM | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Sets New 52-Week High - Here's WhyOctober 22 at 5:54 AM | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading Up 9.3% - What's Next?October 21 at 1:50 PM | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of "Moderate Buy" from AnalystsOctober 21 at 5:47 AM | marketbeat.comInvestors Purchase Large Volume of Arcturus Therapeutics Put Options (NASDAQ:ARCT)October 20 at 11:47 AM | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Upgraded to "Strong-Buy" at Zacks ResearchOctober 15, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 5.6% - Still a Buy?October 14, 2025 | marketbeat.comCiti places ‘upside 90-day catalyst watch’ on Arcturus TherapeuticsOctober 10, 2025 | msn.comArcturus Therapeutics (NASDAQ:ARCT) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Makes New Investment in Arcturus Therapeutics Holdings Inc. $ARCTOctober 7, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 4.7% - Should You Sell?October 6, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up - Here's What HappenedOctober 1, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 9.7% - Here's What HappenedSeptember 29, 2025 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 7.4% - Should You Buy?September 26, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 26, 2025 | marketbeat.comCathie Wood’s ARK Sells Roku and Roblox, Buys Arcturus StockSeptember 25, 2025 | investing.comCathie Wood’s ARK Investment buys 28.3K shares of Arcturus Therapeutics todaySeptember 24, 2025 | msn.comArcturus Therapeutics Shows Progress Amid Transition: Why I Assign A Hold RatingSeptember 23, 2025 | seekingalpha.comGuggenheim Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)September 21, 2025 | theglobeandmail.comLeerink Partners Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)September 21, 2025 | theglobeandmail.comArcturus Therapeutics (NASDAQ:ARCT) Shares Up 5.4% - Here's WhySeptember 17, 2025 | marketbeat.comGoldman Sachs Group Inc. Acquires 42,636 Shares of Arcturus Therapeutics Holdings Inc. $ARCTSeptember 17, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 27.4K shares of Arcturus Therapeutics todaySeptember 16, 2025 | msn.comInnovative Therapeutics Pipeline Positions Industry for Strong Market GrowthSeptember 15, 2025 | finance.yahoo.comDynamic Technology Lab Private Ltd Buys Shares of 28,257 Arcturus Therapeutics Holdings Inc. $ARCTSeptember 15, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. $ARCT Shares Sold by Woodline Partners LPSeptember 14, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $1.53 Million Stake in Arcturus Therapeutics Holdings Inc. $ARCTSeptember 13, 2025 | marketbeat.comBrokers Set Expectations for ARCT Q3 EarningsSeptember 9, 2025 | marketbeat.comInvesco Ltd. Boosts Stock Position in Arcturus Therapeutics Holdings Inc. $ARCTSeptember 8, 2025 | marketbeat.comHC Wainwright Initiates Coverage on Arcturus Therapeutics (NASDAQ:ARCT)September 6, 2025 | marketbeat.comNuveen LLC Purchases New Position in Arcturus Therapeutics Holdings Inc. $ARCTSeptember 6, 2025 | marketbeat.comArcturus Therapeutics assumed with a Buy at H.C. WainwrightSeptember 4, 2025 | msn.comForecasting The Future: 5 Analyst Projections For Arcturus TherapeuticsSeptember 4, 2025 | benzinga.comVestal Point Capital LP Invests $2.24 Million in Arcturus Therapeutics Holdings Inc. $ARCTSeptember 4, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by AnalystsSeptember 2, 2025 | marketbeat.com Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Media Mentions By Week ARCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.370.52▲Average Medical News Sentiment ARCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼255▲ARCT Articles Average Week Get the Latest News and Ratings for ARCT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Arcturus Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Bausch Health Cos News Sarepta Therapeutics News 89BIO News Mesoblast News Ocular Therapeutix News ANI Pharmaceuticals News Vera Therapeutics News Cogent Biosciences News Stoke Therapeutics News Vericel News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.